コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 P assembly may be shared features of SMA and poliomyelitis.
2 ing the risk of vaccine-associated paralytic poliomyelitis.
3 s, encephalitis, and acute flaccid paralysis/poliomyelitis.
4 part of the worldwide campaign to eradicate poliomyelitis.
5 causes a paralytic condition consistent with poliomyelitis.
6 t with a viral encephalomyelitis, similar to poliomyelitis.
7 ing intramuscular injections and provocation poliomyelitis.
8 by the age distribution of the children with poliomyelitis.
9 valuated for induced immunity against type 3 poliomyelitis.
10 an Health Organization as cases of suspected poliomyelitis.
11 imates of the efficacy of these OPVs against poliomyelitis.
12 inate vaccine-associated and vaccine-derived poliomyelitis.
13 otection from paralysis in a murine model of poliomyelitis.
14 al oral human infection leading to paralytic poliomyelitis.
15 elerate eradication and prevent outbreaks of poliomyelitis.
16 alth Assembly resolved to globally eradicate poliomyelitis.
17 on of safety in primate models for paralytic poliomyelitis.
18 and associated increases in the incidence of poliomyelitis.
19 revert to neurovirulence and cause paralytic poliomyelitis.
20 cts of individuals with laboratory-confirmed poliomyelitis, 27 (12.7%) of 213 and 29 (13.9%) of 209 h
21 31, 2011, there were 883 cases of serotype 1 poliomyelitis (710 in Pakistan and 173 in Afghanistan) a
22 Poliovirus (PV) is the causative agent of poliomyelitis, a crippling human disease known since ant
24 eptor (PVR) gene (TgPVR mice), which develop poliomyelitis after intracerebral inoculation, are not s
25 637 days without developing any symptoms of poliomyelitis, after which excretion appeared to have ce
26 rted number of doses received by people with poliomyelitis and by matched controls as identified in N
27 Health (MOH), national surveillance data for poliomyelitis and charts of cases at the national rehabi
28 myelitis due to vaccine-associated paralytic poliomyelitis and circulating vaccine-derived poliovirus
29 for paralytic polio in an animal system for poliomyelitis and have determined the pathogenic mechani
31 quantitatively assessed the epidemiology of poliomyelitis and programme performance and considered t
32 case was defined as a diagnosis of paralytic poliomyelitis and residual paralysis at 60 days in a pat
33 ent oral poliovirus vaccine (OPV) to prevent poliomyelitis and the season when children were vaccinat
34 were collected from children with confirmed poliomyelitis and were used to assess correlates of vacc
35 uropathogenic potential in animal models for poliomyelitis and, at a very low rate, they can cause po
36 , meningitis, septicemia, herpes zoster, and poliomyelitis), and inflammatory (glomerulonephritis, ne
38 gic principles for the global eradication of poliomyelitis are as follows: Poliovirus causes acute, n
39 because oral polio vaccine can rarely cause poliomyelitis as it mutates and may fail to provide adeq
41 surveillance data recording the presence of poliomyelitis associated with wild-type 1 poliovirus in
43 pinal cord anterior horn cells; thus, severe poliomyelitis, but not acute encephalitis, was observed
44 Despite substantial efforts to eradicate poliomyelitis by administering oral poliovirus vaccine t
46 o the PV receptor (PVR) and causes paralytic poliomyelitis by replicating within motor neurons of the
47 be chronically infected with poliovirus, and poliomyelitis can develop despite treatment with intrave
48 Sabin vaccine strains used in prevention of poliomyelitis carry such mutations in their IRES element
52 io, Pakistan bears the highest proportion of poliomyelitis cases among the 3 endemic countries includ
53 us and reasons for undervaccination among 66 poliomyelitis cases and 130 age- and neighborhood-matche
55 d lead to roughly 200 000 expected paralytic poliomyelitis cases every year in low-income countries,
59 , which is consistent with recent absence of poliomyelitis cases; whereas seroprevalence against type
61 hed case-control pairs of confirmed cases of poliomyelitis caused by type 1 wild poliovirus and cases
64 for the Certification of the Eradication of Poliomyelitis certified the eradication of type 2 poliov
66 irus vaccines led to a stepwise reduction in poliomyelitis, culminating in the unpredicted eliminatio
68 one of the compounds in an in vivo model of poliomyelitis demonstrated partial protection from the o
71 accine (OPV) results in an ongoing burden of poliomyelitis due to vaccine-associated paralytic poliom
74 stigations included the study of the Buffalo poliomyelitis epidemic of 1912, by Wade Hampton Frost, w
75 sion for the Certification of Eradication of Poliomyelitis Eradication (ICCPE) was established by the
76 national Commission for the Certification of Poliomyelitis Eradication declared the Americas to be po
78 ay become relevant during the final phase of poliomyelitis eradication in populations with predominan
79 Regional Commission for the Certification of Poliomyelitis Eradication in the Western Pacific certifi
80 resolution on intensification of the Global Poliomyelitis Eradication Initiative (GPEI), the Nigeria
83 ental surveillance (ES) of poliovirus in the poliomyelitis eradication strategic plan as an activity
84 ed data on 2296 cases of GBS reported to the Poliomyelitis Eradication Surveillance System of the Pan
87 of combined diphtheria-tetanus-pertussis and poliomyelitis expanded vaccines with the first of three
88 duced population immunity against serotype-2 poliomyelitis for 1 January 2004-30 June 2015 and produc
97 likely to protect >80% of recipients against poliomyelitis if poliovirus reemerges after withdrawal o
99 to detect poliovirus infections or paralytic poliomyelitis in Amish communities in Minnesota, neighbo
100 on is evidenced by the documented absence of poliomyelitis in an increasing number of countries and t
103 e the key factors sustaining transmission of poliomyelitis in Nigeria and to calculate clinical effic
106 e likelihood of vaccine-associated paralytic poliomyelitis in recipients of live attenuated polioviru
111 rns are important determinants of historical poliomyelitis incidence in Pakistan; however, movement d
113 (radiation) was a significant determinant of poliomyelitis incidence, it did not improve the predicti
115 lenges to the final eradication of paralytic poliomyelitis include the continued transmission of wild
116 erve as a possible determinant of widespread poliomyelitis infection in Pakistan and further emphasiz
121 recapitulates human poliovirus infection and poliomyelitis, it can be used to study polio pathogenesi
122 recapitulates human poliovirus infection and poliomyelitis, it can be used to study polio pathogenesi
123 t patients with vaccine-associated paralytic poliomyelitis (iVAPP), cases reported in the United Stat
125 foot, and mouth disease, aseptic meningitis, poliomyelitis-like acute flaccid paralysis, brainstem en
127 as WNV-infected humans can also experience a poliomyelitis-like disease where motor neurons are damag
128 t ever outbreak of West Nile encephalitis; a poliomyelitis-like flaccid paralysis due to West Nile vi
132 04) data for diphtheria, pertussis, tetanus, poliomyelitis, measles, mumps, rubella (including congen
133 r 1991 and March 1992, 37 cases of paralytic poliomyelitis occurred in Jordan, where none had been re
135 ination against diphtheria-tetanus-pertussis-poliomyelitis (OR = 1.5) and was not statistically signi
139 sights into the dynamics of future potential poliomyelitis outbreaks and in this way serve as a usefu
140 ulating vaccine-derived PVs that have caused poliomyelitis outbreaks in different parts of the world.
141 rd eradication of poliomyelitis, the risk of poliomyelitis outbreaks resulting from virus importation
142 cine-derived poliovirus (VDPV), which causes poliomyelitis outbreaks similar to those caused by wild
144 ssed their association with the incidence of poliomyelitis over time in seven regions of Afghanistan
145 olates obtained over a 337-day period from a poliomyelitis patient from Taiwan with common variable i
146 olates obtained over a 189-day period from a poliomyelitis patient with common variable immunodeficie
147 e-derived isolates from an immunocompromised poliomyelitis patient, the contacts, and the local sewag
151 s from cases of vaccine-associated paralytic poliomyelitis related to the CHAT vaccine revealed genet
153 contact with 2761 individuals with suspected poliomyelitis reported during the period 2003-2008.
154 rus has caused meningitis, encephalitis, and poliomyelitis, resulting in significant morbidity and mo
155 offs among different strategies for managing poliomyelitis risks after they succeed with polio eradic
156 e the success of current vaccination against poliomyelitis, safe, cheap and effective vaccines remain
157 tan and 173 in Afghanistan) and 272 cases of poliomyelitis serotype 3 (216 in Pakistan and 56 in Afgh
158 lateral sclerosis or West Nile Virus-induced poliomyelitis, suggesting a common tissue injury pathway
159 e substantial progress toward eradication of poliomyelitis, the risk of poliomyelitis outbreaks resul
160 persons (iVDPV) presents a personal risk of poliomyelitis to the patient as well as a programmatic r
161 ous population immunity continued to support poliomyelitis transmission in Nigeria at the end of 2012
162 -to introduce at least 1 dose of inactivated poliomyelitis vaccine (IPV); withdraw oral poliomyelitis
163 d poliomyelitis vaccine (IPV); withdraw oral poliomyelitis vaccine (OPV), starting with the type 2 co
164 oradic cases of vaccine-associated paralytic poliomyelitis (VAPP) and the emergence of genetically di
165 f patients with vaccine-associated paralytic poliomyelitis (VAPP) in Hungary during 1961-1981 were re
166 e rare cases of vaccine-associated paralytic poliomyelitis (VAPP) in OPV recipients and their close c
168 e of 9 cases of vaccine-associated paralytic poliomyelitis (VAPP) were confirmed each year from 1961
172 f a dose of trivalent OPV against serotype 1 poliomyelitis was 12.5% (95% CI 5.6-18.8) compared with
174 The vaccination history of children with poliomyelitis was compared with that of children with ac
177 poliovirus vaccine against type 1 paralytic poliomyelitis were 67% (95% confidence interval [CI], 39
178 oliomyelitis was investigated: Patients with poliomyelitis were evaluated, the extent of poliovirus c
180 rom 1990 through 1999, 61 cases of paralytic poliomyelitis were reported; 59 (97%) of these were VAPP
182 therefore be used in eradicating serotype 1 poliomyelitis whilst minimising the risks of serotype 3
183 e vaccinated, 46 children 1-7 years old with poliomyelitis who had received three card-documented dos
184 During 1976-1995, 48 outbreaks of paralytic poliomyelitis with a cumulative total of approximately 1
185 on and presents a disease pattern resembling poliomyelitis with seasonal epidemics that include cases
187 transmission of wild polioviruses (WPVs) and poliomyelitis, with the last case of WPV type 2 in the w
188 viduals was associated with the incidence of poliomyelitis, with the radiation model of movement prov
189 ic phenotype in a transgenic mouse model for poliomyelitis without diminishing the growth properties
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。